Repository logo
 
Publication

Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects

2014Conference object Restricted access
Simple item page
dc.contributor.authorMarques, C.
dc.contributor.authorMega, C.
dc.contributor.authorGonçalves, A.
dc.contributor.authorRodrigues-Santos, P.
dc.contributor.authorVala, Helena
dc.contributor.authorTeixeira-Lemos, E.
dc.contributor.authorTeixeira, F.
dc.contributor.authorFontes-Ribeiro, C.
dc.contributor.authorReis, F.
dc.contributor.authorFernandes, R.
dc.date.accessioned2015-03-23T10:08:22Z
dc.date.available2015-03-23T10:08:22Z
dc.date.issued2014
dc.description.abstractObjective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat. Methods: ZDF rats (aged 20 weeks) were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia, HbA1c, urea and creatinine levels were monitored. Kidney glomerular and tubulointerstitial lesions were assessed using a semiquantitative rating. Kidney mRNA and/or protein content of DPP-IV, GLP-1, TNF-α, IL-1β, BAX, Bcl-2 and Bid were evaluated by RT-PCR and/or WB. Protein distribution was evaluated by immunohistochemistry. Results: Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c, and prevented the diabetes-induced increase in DPP-IV levels and decrease in GLP-1 levels. Sitagliptin ameliorated diabetes-induced glomerular atrophy and IFTA, and the increased urea levels. Sitagliptin decreased kidney IL-1β and TNF-α, and prevented the increase of BAX/Bcl-2 ratio and Bid protein levels, which indicates protective effects against inflammation and pro-apoptotic state in the kidney of diabetic rats, respectively. Conclusion: Sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and anti-apoptotic properties.por
dc.description.sponsorshipFCT Portugal (PEst-C/SAU/UI3282/2011, PEst-C/SAU/UI3282/2013, COMPETE; CI&DETS - PEst-OE/CED/UI4016/2014)por
dc.identifier.citationC. Marques, C. Mega, A. Gonçalves, P. Rodrigues-Santos, H. Vala, E. Teixeira-Lemos, F. Teixeira, C. Fontes-Ribeiro, F. Reis and R. Fernandes (2014). Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects. Virchows Arch 465 (Supll I): S261 IF 2012 2.676por
dc.identifier.urihttp://hdl.handle.net/10400.19/2715
dc.language.isoengpor
dc.peerreviewedyespor
dc.subjectsitagliptinpor
dc.subjectZucker Diabetic Fatty (ZDF) ratpor
dc.subjectanimal model of T2DMpor
dc.subjectdipeptidyl peptidase IV (DPP-IV) inhibitorpor
dc.titleSitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effectspor
dc.typeconference object
dspace.entity.typePublication
oaire.citation.titleVirchows Archpor
oaire.citation.volume465 (Supll I)por
person.familyNameVala Correia
person.givenNameHelena Maria
person.identifier.ciencia-id7A1E-E85E-FFA4
person.identifier.orcid0000-0001-6829-4867
rcaap.rightsrestrictedAccesspor
rcaap.typeconferenceObjectpor
relation.isAuthorOfPublicationcdc3d2e2-df06-40ed-8900-1ecbc8a06c8a
relation.isAuthorOfPublication.latestForDiscoverycdc3d2e2-df06-40ed-8900-1ecbc8a06c8a

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
52 Sita ameliorates kidney ESP 14.pdf
Size:
1.65 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESAV - DZERV - Documentos de congressos (comunicações, posters, actas)